Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 2

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 2
---
us is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

1,000,000 Ordinary Shares

Regentis Biomaterials Ltd.

This is a firm commitment initial public offering of ordinary shares,
no par value, or Ordinary Shares, of Regentis Biomaterials Ltd. The anticipated initial public offering price will be between $10.00 and
$12.00 per Ordinary Share. The number of Ordinary Shares offered hereby is based upon an assumed initial offering price of $11.00 per
Ordinary Share, the midpoint of such estimated price range. For a discussion of the factors to be considered in determining the initial
public offering price of the Ordinary Shares, see “Underwriting”.

Prior to this offering, there has been no
public market for our Ordinary Shares. Our Ordinary Shares have been approved for listing on the NYSE American under the symbol “RGNT”.

We are both an emerging growth company, as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a “foreign private issuer,” as defined under the
U.S. federal securities laws and are subject to reduced public company reporting requirements. See “Prospectus Summary—Implications
of Being an Emerging Growth Company and a Foreign Private Issuer” for additional information.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 14.

None of the Securities and Exchange Commission, or the SEC, the Israeli Securities Authority, or any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                  |     | Per Share |     | Total |
|:---------------------------------|:----|:----------|:----|:------|
| Initial public offering price    |     | $         |     | $     |
| Underwriting discounts and       
 commissions (1)                  |     | $         |     | $     |
| Proceeds to us (before expenses) |     | $         |     | $     |

| (1) | Underwriting discounts and                                                                                                       
 commissions do not include a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the 
 underwriters. We refer you to “Underwriting” beginning on page 133 for additional information regarding underwriters’            
 compensation